These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment. Citrome L; Saklad SR J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32078259 [TBL] [Abstract][Full Text] [Related]
11. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568 [TBL] [Abstract][Full Text] [Related]
12. Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy. Musco S; Ruekert L; Myers J; Anderson D; Welling M; Cunningham EA J Clin Psychopharmacol; 2019; 39(4):336-343. PubMed ID: 31205194 [TBL] [Abstract][Full Text] [Related]
13. Deutetrabenazine in the treatment of tardive dyskinesia. Niemann N; Jimenez-Shahed J Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019 [TBL] [Abstract][Full Text] [Related]
17. Integrative approach for managing tardive dyskinesia: A case report. Kulamarva K; Karanth V; Chikkanna U; Bhargav H; Holla B; Ramakrishna KK; Jasti N; Varambally S Explore (NY); 2023; 19(6):865-867. PubMed ID: 37217392 [TBL] [Abstract][Full Text] [Related]
18. Valbenazine in the treatment of tardive dyskinesia. Witek N; Comella C Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115 [TBL] [Abstract][Full Text] [Related]
19. Valbenazine for the treatment of tardive dyskinesia. Seeberger LC; Hauser RA Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794 [TBL] [Abstract][Full Text] [Related]
20. Clinical risk factors for the development of tardive dyskinesia. Solmi M; Pigato G; Kane JM; Correll CU J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]